RBSH (Rebus Hldgs) FCF Margin %: 0.00% (As of Jun. 2023)


What is Rebus Hldgs FCF Margin %?

Rebus Hldgs RBSH FCF Margin % is 0.00% as of Jun. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Rebus Hldgs's Free Cash Flow for the three months ended in Jun. 2023 was $0.00 Mil. Rebus Hldgs's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Rebus Hldgs's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, Rebus Hldgs's current FCF Yield % is 0.00%.

The historical rank and industry rank for Rebus Hldgs's FCF Margin % or its related term are showing as below:


RBSH's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Rebus Hldgs FCF Margin % Related Terms

Rebus Hldgs FCF Margin % Historical Data

* Premium members only.

The historical data trend for Rebus Hldgs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rebus Hldgs FCF Margin % Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RBSH vs KRBP, CNBX, EVFM: FCF Margin % Comparison

For the Biotechnology subindustry, Rebus Hldgs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rebus Hldgs FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's FCF Margin % falls into.


Rebus Hldgs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Rebus Hldgs's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-0.706/0
= %

Rebus Hldgs's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Rebus Hldgs (RBSH) has a FCF Margin % of 0.00% as of Jun. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rebus Hldgs and its competitors.
Is Rebus Hldgs' FCF Margin % too high?
Rebus Hldgs' current FCF Margin % is 0.00%.
How does Rebus Hldgs' FCF Margin % compare to KRBP and CNBX?
Rebus Hldgs' FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rebus Hldgs and its competitors. Rebus Hldgs's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rebus Hldgs stock overvalued right now?
Rebus Hldgs (RBSH) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Rebus Hldgs (RBSH), the current FCF Margin % is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rebus Hldgs Business Description

Address 2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.